Table III.
Risk of cancer subgroups according to p53 Arg72Pro genotype in the general population
|
|
|
|
Arg/Arg
|
Arg/Pro
|
Pro/Pro
|
||
|---|---|---|---|---|---|---|---|
| Endpoint | Participants | Events | HR | HR (95% CI) |
p-value | HR (95% CI) |
p-value |
| Gastrointestinal cancer | 9,219 | 391 | 1.0 | 1.10 (0.89–1.34) |
0.38 | 0.89 (0.58–1.37) |
0.59 |
| Hematologic cancer | 9,218 | 112 | 1.0 | 2.01 (1.36–2.98) |
<0.001a | 1.49 (0.70–3.17) |
0.30 |
| Respiratory cancer | 9,219 | 271 | 1.0 | 0.91 (0.71–1.17) |
0.47 | 0.82 (0.49–1.38) |
0.46 |
| Urologic cancer | 9,217 | 185 | 1.0 | 1.10 (0.82–1.48) |
0.53 | 0.73 (0.37–1.45) |
0.37 |
| Female cancer | 5,155 | 477 | 1.0 | 1.06 (0.88–1.28) |
0.51 | 0.71 (0.46–1.07) |
0.10 |
| Male cancer | 4,114 | 136 | 1.0 | 1.11 (0.79–1.58) |
0.55 | 1.15 (0.59–2.23) |
0.68 |
| Other cancer | 9,219 | 659 | 1.0 | 1.09 (0.93–1.28) |
0.30 | 1.00 (0.73–1.37) |
0.98 |
Hazard ratios were adjusted for gender (when relevant) and age in all analyses. Follow-up started January 1, 1947, at the establishment of the Danish Cancer Registry or at birth, whichever came last, and ended at the date of the first relevant cancer diagnosis, death, emigration, or December 31, 2002, whichever came first. Numbers of participants vary slightly because some participants were excluded as a result of the development of disease before follow-up. HR, hazard ratio; CI, confidence interval.
a
Remained statistically significant (P < 0.05) after Bonferroni correction for multiple comparison for 14 tests.